Study of NGR-hTNF as Single Agent in Patients Affected by Advanced or Metastatic Hepatocellular Carcinoma (HCC)
The main objective of the trial is to document the progression free survival (PFS) in advanced or metastatic hepatocellular carcinoma patients treated with NGR-hTNF as single agent.

Safety will be established by clinical and laboratory assessment according to NCI-CTC criteria
Hepatocellular Carcinoma
DRUG: NGR-hTNF
Antitumour activity defined as progression free survival (PFS), during the study
Tumor growth control rate (TGCR) according to WHO criteria, during the study|Pharmacokinetics in patients treated with weekly schedule, during treatment|Safety, during the study|Overall survival (OS), During the treatment and during the follow-up|Experimental imaging study (DCE-MRI), During the treatment
This is a phase II, open-label, non-randomized study that will be conducted in patients affected by advanced or metastatic Hepatocellular Carcinoma (HCC) previously treated with no more than one systemic therapeutic regimen, that will be conducted using Simon's two-stage design method.